SubsidieMeestersHigh-throughput combinatory drugs testing on in vitro 3D cells model platform
The project aims to develop a microfluidic platform for high-throughput screening of drug combinations in 3D cultures to enhance drug discovery and identify synergistic therapies for breast cancer.
Projectdetails
Introduction
Drug combinations can lead to the discovery of novel drugs by increasing efficacy or lowering toxicity through synergy. This can boost existing drugs, rescue drug candidates, and accelerate drug discovery for yet poorly addressed diseases. However, predicting synergy is difficult, and finding synergies requires high-throughput screening (HTS) in advanced cell models.
Current Solutions
Current solutions propose either HTS in 2D cell cultures or low throughput assays in 3D cell cultures, but not both.
Innovative Technology
On the basis of a technology developed in the ERC-funded AbioEvo project, we devised an innovative microfluidic platform for 3D culture and HTS of drug combinations.
Advantages of the Platform
- Miniaturization densifies routine 3D assays, resulting in a throughput increase of 10 to 100 times.
- Fluidic automation reduces liquid handling 500 times for a 100x100 drug library at a 10-point dose-response combinatorial screening.
- 3D culture models better predict later physiological responses, thus increasing the success probability of downstream drug development stages.
We have shown dose-response measurements of 144 antibiotic combinations on bacteria on a single chip.
Project Objectives
In this POC, we aim to demonstrate the applicability of our technology to human cells and benchmark it based on existing screens for breast cancer cells.
Planned Activities
- Adapt the cell culture conditions and data analysis.
- Perform market analysis.
- Examine industrialization feasibility.
This will put us in a position to create a spin-off to reach the preclinical drug screening market and identify the most promising therapeutic areas.
Conclusion
Indeed, the technology has the potential to screen for synergistic drug combinations at an earlier stage of the drug discovery process (thanks to miniaturization and automation) while providing a more reliable cellular response for later stages (thanks to 3D culture).
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-1-2023 |
| Einddatum | 30-6-2024 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- ECOLE SUPERIEURE DE PHYSIQUE ET DECHIMIE INDUSTRIELLES DE LA VILLE DEPARISpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Learning and modeling the molecular response of single cells to drug perturbationsDeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings. | ERC ADG | € 2.497.298 | 2023 | Details |
Bringing 3D cardiac tissues to high throughput for drug discovery screensDeveloping a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability. | EIC Transition | € 1.457.500 | 2023 | Details |
Dypha: adding the dimension of time to cell cultureThe δypha System aims to enhance drug development by providing a plug-and-play microfluidic adaptor for 96 well plates, enabling precise control of fluid kinetics in cell culture models. | EIC Transition | € 2.499.625 | 2024 | Details |
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug developmentCherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing. | EIC Accelerator | € 2.499.831 | 2024 | Details |
Learning and modeling the molecular response of single cells to drug perturbations
DeepCell aims to model cellular responses to drug perturbations using multiomics and deep learning, facilitating optimal treatment design and expediting drug discovery in clinical settings.
Bringing 3D cardiac tissues to high throughput for drug discovery screens
Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.
Dypha: adding the dimension of time to cell culture
The δypha System aims to enhance drug development by providing a plug-and-play microfluidic adaptor for 96 well plates, enabling precise control of fluid kinetics in cell culture models.
Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development
Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.